Search

Objective: The global prevalence of nontuberculous mycobacterial pulmonary disease (NTM-PD) has been steadily increasing. A few small retrospective studies have reported a poor prognosis associated with chronic pulmonary aspergillosis (CPA) as a complication of NTM-PD. Furthermore, the prognostic impact of CPA may have been inadequately assessed due to differences in background factors. This study aimed to identify the risk factors for CPA in NTM-PD and compare the risk of in-hospital mortality between patients with and without aspergillosis., Methods: Data were obtained from a large-scale claims database. Patients with NTM-PD who met the inclusion criteria and those who developed CPA after the NTM diagnosis were identified. The incidence of CPA was evaluated, and risk factors were identified using multiple logistic analyses. Mortality rates were evaluated and compared between patients with and without aspergillosis after adjusting for background CPA risk factors., Results: The incidence of CPA was 2.29% (265/11,587). The identified risk factors included male sex, chronic respiratory failure, asthma, interstitial pneumonia, pulmonary tuberculosis sequelae and systemic corticosteroid use. A total of 219 patients with CPA were matched with control cases using propensity scores based on age and identified risk factors for CPA. The adjusted hazard ratio for in-hospital mortality was 2.6 (95% CI: 1.8-3.9)., Conclusions: CPA as a complication of NTM-PD is associated with significantly higher mortality rates. Clinicians should consider the necessity of promptly diagnosing CPA in patients with NTM-PD and the associated risk factors., (© 2025 Wiley‐VCH GmbH. Published by John Wiley & Sons Ltd.)

Sargramostim, a recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) inhalation therapy, was recently approved for pharmaceutical use in Japan and shows promise as a treatment for autoimmune pulmonary alveolar proteinosis (APAP). For APAP patients with severe respiratory failure due to advanced lung fibrosis, lung transplantation is also a treatment option; however, APAP may recur after the procedure. Here, we report a case of successful sargramostim inhalation therapy for post-transplant APAP relapse in a patient who underwent living lung transplantation owing to severe fibrosis. Inhaled GM-CSF may be a useful treatment option for APAP recurrence in patients who have undergone lung transplantation. CLINICAL TRIAL REGISTRATION: Pulmonary Alveolar Proteinosis GM-CSF Inhalation Efficacy Trial II registered to Japan Registry of Clinical Trials (jRCTs031220127)., Competing Interests: Declaration of competing interest K.N has received funding from Nobelpharma, and consulting fees from Nobelpharma unrelated to the present manuscript. The other authors have no conflicts of interest., (Copyright © 2024 [The Author]. Published by Elsevier B.V. All rights reserved.)

Background: No previous studies have compared respiratory clinics and respiratory specialized facilities regarding causative diseases for bloody sputum and hemoptysis in Japan., Methods: We retrospectively compared causative diseases for bloody sputum and hemoptysis between 3 respiratory clinics (clinic group) and 7 departments of respiratory medicine at hospitals (hospital group) in Japan., Results: We collected data from 231 patients (median age, 51 years; age range, 24-96 years; 109 men (47.2%)) in the clinic group and 556 patients (median age, 73 years; age range, 21-98 years; 302 men (54.3%)) in the hospital group. In the former group, the main causative disease was acute bronchitis (91 patients, 39.4%), acute upper respiratory tract infection (34 patients, 14.7%), and bronchiectasis (BE) (29 patients, 12.6%). In the latter group, the main causative diseases were BE (102 patients, 18.3%), lung cancer (97 patients, 17.4%), and non-tuberculous mycobacterial disease (NTM) (89 patients, 16%). In particular, in patients ≥60 years old, BE was an important causative disease for bloody sputum and hemoptysis in both groups., Conclusions: The present study is the first to compare respiratory clinics and respiratory specialized facilities. Depending on the facility in which the patient is examined, lung cancer, BE, and NTM were identified as diseases requiring special attention as causes of bloody sputum and hemoptysis., Competing Interests: Conflict of interest KT received a Grant-in-Aid for Scientific Research from Ministry of Health, Labour and Welfare (No. 20K08545). The other authors have no conflicts of interest., (Copyright © 2024. Published by Elsevier B.V.)